Showing results (121-130 of 128) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 128 results.
ESMO Open|July 22, 2020
Nivolumab treatment of elderly Japanese patients with non-small cell lung cancer: subanalysis of a real-world retrospective observational study (CA209-9CR)Kyoichi Okishio, Ryo Morita, Junichi Shimizu, et al.
The Lancet. Respiratory Medicine|August 29, 2021
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trialYosuke Kawashima, Tatsuro Fukuhara, Haruhiro Saito, et al.
Lung Cancer (Amsterdam, Netherlands)|December 16, 2019
Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in JapanRyo Morita, Kyoichi Okishio, Junichi Shimizu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 7, 2024
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON TrialSolange Peters, Byoung Chul Cho, Alexander V Luft, et al.
JAMA Oncology|December 21, 2023
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical TrialYoshimasa Shiraishi, Junji Kishimoto, Shunichi Sugawara, et al.
Ebiomedicine|July 7, 2020
Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 studyTatsuro Fukuhara, Haruhiro Saito, Naoki Furuya, et al.
Lung Cancer (Amsterdam, Netherlands)|May 13, 2026
Final overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancerYoshimasa Shiraishi, Junji Kishimoto, Shunichi Sugawara, et al.
Molecular Oncology|October 21, 2023
NOTCH1 and CREBBP co-mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR-mutated NSCLC: translational research of phase III IMPACT studySatoshi Ikeda, Masahiro Tsuboi, Kazuko Sakai, et al.
Pageof 13